Your browser doesn't support javascript.
loading
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.
Prescott, Eva; Angerås, Oskar; Erlinge, David; Grove, Erik L; Hedman, Marja; Jensen, Lisette O; Pernow, John; Saraste, Antti; Åkerblom, Axel; Svedlund, Sara; Rudvik, Anna; Knöchel, Jane; Lindstedt, Eva-Lotte; Garkaviy, Pavlo; Gan, Li-Ming; Gabrielsen, Anders.
Afiliação
  • Prescott E; Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: epre0004@regionh.dk.
  • Angerås O; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, and Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Erlinge D; Cardiology, Department of Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
  • Grove EL; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
  • Hedman M; Heart Center and Clinical Imaging Center, Kuopio University Hospital, Kuopio, Finland; Institute of Medicine, University of Eastern Finland, Kuopio, Finland.
  • Jensen LO; Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • Pernow J; Division of Cardiology, Department of Medicine, Karolinska Institute, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Saraste A; University of Turku and Heart Centre, Turku University Hospital, Turku, Finland.
  • Åkerblom A; Department of Medical Sciences - Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Svedlund S; Department of Clinical Physiology, Sahlgrenska University Hospital and Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Rudvik A; Early Biometrics and Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Knöchel J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lindstedt EL; Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Garkaviy P; Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Gan LM; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, and Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Goth
  • Gabrielsen A; Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Int J Cardiol ; 365: 34-40, 2022 10 15.
Article em En | MEDLINE | ID: mdl-35842004
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Proteína Ativadora de 5-Lipoxigenase / Infarto do Miocárdio Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Proteína Ativadora de 5-Lipoxigenase / Infarto do Miocárdio Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article